Authors: Laura Pietrangelo, IreneMagnifico, AntonellaGuerrera, Marco Alfio Cutuli, Giulio Petronio Petronio, Noemi Venditti, Matteo Covelli, Nicandro Buccieri, Silvio Garofalo, RobertoDi Marco

Institutions:

  • Università degli Studi del Molise, Dipartimento di Medicina e Scienze della Salute “V. Tiberio”, Campobasso, Italy
  • Gea Medica srl, Istituto Europeo di Riabilitazione, Isernia, Italy
  • UOC Laboratorio Analisi P.O. “A. Cardarelli”, Campobasso, Italy

Publication: Biomedicine & Pharmacotherapy

Date: December 2021

Full paper: https://www.sciencedirect.com/science/article/pii/S0753332221011112

Abstract:

Pressure ulcers development is an undesirable event that often worsens the clinical condition of patients already affected by severe pathologies. Since the aetiology of this clinical complication is unclear yet, at current the primary approach to treat the problem is the adoption of suitable patients’ assistance procedures. At the same time, the research focuses on finding medicaments or treatment strategies that could prevent the lesions and/or accelerate their healing. The international market’s wide range of cosmetic/pharmaceuticals products is mainly topical preparations based on emollient agents to preserve or restore skin homeostasis. On the other hand, the skin microbiome’s implication in the pressure ulcers occurrence is mainly unknown. Based on these assumptions, here we tested an innovative preparation, the LimpiAD foam, as a potential preventive strategy of pressure ulcers onset. The active component of this product is composed of hyaluronic acid conjugated with a bacterial cell wall fragment of C. acnes DSM 28251. For LimpiAD foam, we hypothesised a combined action of the two components on the skin tissue, an emollient effect due to the hyaluronic acid properties together with a modulatory effect on the skin microbiota carried out by the component of bacterial derivation. Our results supported the hypothesis and suggested a potential role of LimpiAD foam in pressure ulcers prevention.